Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 153.56M | 124.45M | 48.58M | -75.86M | -132.62M |
| Total Depreciation and Amortization | 33.68M | 34.24M | 34.65M | 34.49M | 35.24M |
| Total Amortization of Deferred Charges | 3.79M | 3.22M | 2.91M | 2.69M | 2.76M |
| Total Other Non-Cash Items | -65.92M | -99.88M | -43.88M | 86.66M | 141.55M |
| Change in Net Operating Assets | -1.61M | -12.67M | -10.35M | 7.38M | 5.95M |
| Cash from Operations | 123.50M | 49.36M | 31.92M | 55.36M | 52.87M |
| Capital Expenditure | -466.00K | -452.00K | -1.16M | -1.74M | -1.93M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -8.09M | -8.09M | -- | -- | -- |
| Other Investing Activities | -468.01M | -368.79M | -396.69M | -89.17M | -133.07M |
| Cash from Investing | -476.56M | -377.32M | -397.84M | -90.90M | -135.00M |
| Total Debt Issued | 460.00M | 460.00M | 460.00M | -- | -- |
| Total Debt Repaid | -113.28M | -113.28M | -113.28M | -30.00K | -27.00K |
| Issuance of Common Stock | 50.93M | 47.50M | 60.65M | 90.33M | 91.65M |
| Repurchase of Common Stock | -37.44M | -24.60M | -26.19M | -11.10M | -10.95M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 58.62M | 58.60M | 59.10M | 6.51M | -456.00K |
| Cash from Financing | 418.84M | 428.22M | 440.28M | 85.72M | 80.21M |
| Foreign Exchange rate Adjustments | 1.26M | 2.36M | 1.40M | 2.18M | -113.00K |
| Miscellaneous Cash Flow Adjustments | 78.00K | 0.00 | 0.00 | -2.82M | -78.00K |
| Net Change in Cash | 67.11M | 102.62M | 75.76M | 49.53M | -2.10M |